Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Merck & Co., Inc. — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.36 (market cap $77.43B), while Merck & Co., Inc. trades at $146.2 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4.5× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Merck & Co., Inc. for 98 Days on average.
| MDLZ | MRK | |
|---|---|---|
Market Cap | $77.43B | $351.28B |
Volume | 7,695,104 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $156.43 |
52-Week Low | $51.51 | $82.49 |
Typical Hold Time | 107 Days | 98 Days |
Enterprise Value | $97.78B | $398.04B |
Dividend Yield | 3.43% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.41, up 1.73% with a bullish technical signal. The company shows strong fundamentals with consistent earnings beats, $38.54B in 2025 revenue, and improving cash flow. Analyst consensus is strongly bullish with a $70.29 price target. Recent developments include a dividend increase to $0.52 and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling investment case with solid profitability (8.86% net margin), attractive valuation (P/E 22.22), and strong analyst support. Key risks include cocoa cost pressures and competitive threats. The stock offers upside potential to consensus targets while providing defensive characteristics in volatile markets.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
